Bristol-Myers Squibb Company ((BMY)) announced an update on their ongoing clinical study.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Study Overview: Bristol-Myers Squibb Company is conducting a Phase I study titled ‘Phase I Multicenter, Open-Label, First-in-Human Study of BMS-986497 (ORM-6151) as a Monotherapy, in Double Combination With Azacitidine and in Triple Combination With Azacitidine and Venetoclax in Subjects With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome.’ The study aims to assess the safety, tolerability, drug levels, and efficacy of BMS-986497, determining the recommended dose for patients with relapsed or refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).
Intervention/Treatment: The study tests BMS-986497 both as a monotherapy and in combination with other drugs. The combinations include Azacitidine and Venetoclax, targeting improved treatment outcomes for AML and MDS patients.
Study Design: This interventional study is non-randomized and follows a sequential intervention model with no masking. Its primary purpose is treatment, focusing on evaluating the new drug’s effects in a controlled setting.
Study Timeline: The study began on May 29, 2024, with the latest update submitted on June 30, 2025. These dates are crucial as they mark the progression and ongoing status of the trial, providing a timeline for potential results and developments.
Market Implications: The study’s progress could significantly impact Bristol-Myers Squibb’s stock performance, as successful outcomes may enhance their portfolio in the oncology sector. Investors should watch for updates, as positive results could shift market dynamics, especially in the competitive landscape of cancer treatments.
The study is currently recruiting, with further details available on the ClinicalTrials portal.